Recent 8-K filings for PFE

• May 5, 2026, 7:59 PM ET earnings materiality 0.65 neutral item 2.02item 9.01 ◈ Earnings Releases

  Pfizer Q1 revenue $14.5B (+2% op); adj EPS $0.75 (-18%); reaffirms FY26 guidance

  Revenue $14.45B, up 2% operationally; ex-COVID products grew 7% op; launched/acquired products up 22% op.

• February 3, 2026, 6:59 PM ET earnings materiality 0.70 neutral item 2.02item 9.01

  Pfizer reports FY2025 revenue $62.6B, adj. EPS $3.22; reaffirms FY2026 guidance

  Full-year 2025 revenue $62.6B (-2% operational); non-COVID portfolio +6% operational.

• December 16, 2025, 6:59 PM ET earnings materiality 0.65 negative item 7.01item 9.01

  Pfizer revises FY2025 revenue to ~$62B (from $61-64B), provides FY2026 EPS guidance $2.80-3.00

  Revised FY2025 revenue guidance to ~$62.0B from prior $61-64B; reaffirmed adjusted diluted EPS $3.00-3.15.

• November 21, 2025, 6:59 PM ET debt materiality 0.80 neutral item 8.01item 9.01

  Pfizer completes $6.0 billion offering of notes due 2027-2065

  Issued $500M Floating Rate Notes due 2027, $1B 3.875% Notes due 2027, $1B 4.200% Notes due 2030

• November 13, 2025, 6:59 PM ET M&A materiality 0.75 neutral item 8.01

  Pfizer completes $7B acquisition of Metsera, including contingent milestones up to $20.65/sh

  Enterprise value ~$7.0B; each Metsera share converted into $65.60 cash at closing.

• November 4, 2025, 6:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Pfizer Q3 adj EPS $0.87 beat; raises FY adj EPS guidance to $3.00-$3.15; sues Novo Nordisk over Metsera

  Q3 revenues $16.7B (-7% operational YoY); reported EPS $0.62, adj EPS $0.87.

• August 5, 2025, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Pfizer Q2 2025 revenue $14.7B (+10% YoY); raises FY adjusted EPS guidance to $2.90-$3.10

  Reported diluted EPS $0.51; adjusted diluted EPS $0.78, up 30% YoY.

• May 19, 2025, 7:59 PM ET debt materiality 0.65 neutral item 8.01item 9.01

  Pfizer subsidiary completes €3.3B debt offering in four tranches

  Issued €750M 2.875% notes due 2029, €1B 3.250% notes due 2032, €750M 3.875% notes due 2037, €800M 4.250% notes due 2045.

• April 29, 2025, 7:59 PM ET other material materiality 0.70 neutral item 2.02item 2.05item 9.01

  Pfizer Q1 revenues $13.7B (-8% YoY), adjusted EPS $0.92 (+12%); reaffirms FY2025 guidance

  Q1 revenues $13.7B, down 8% YoY; reported diluted EPS $0.52 (down 5%), adjusted diluted EPS $0.92 (up 12%).

• February 4, 2025, 6:59 PM ET earnings materiality 0.75 positive item 2.02item 9.01

  Pfizer Q4/FY2024 rev $63.6B (+7% op); adj EPS $3.11; reaffirms 2025 guidance

  FY2024 revenues $63.6B (+7% operational); excluding COVID products, up 12% operationally.

• December 17, 2024, 6:59 PM ET other material materiality 0.75 positive item 7.01item 9.01

  Pfizer provides 2025 revenue guidance $61-64B, adj. EPS $2.80-3.00

  Full-year 2025 revenue guidance range of $61.0 to $64.0 billion, with operational growth approximately flat to 5% year-over-year.

• October 29, 2024, 7:59 PM ET earnings materiality 0.85 positive item 2.02item 9.01

  Pfizer Q3 revenue $17.7B (+32% YoY); raises FY 2024 guidance on revenue and EPS

  Q3 2024 revenues of $17.7B, operational growth +32% YoY; ex-Paxlovid/Comirnaty revenue up 14% operationally.

• July 30, 2024, 7:59 PM ET earnings materiality 0.80 positive item 2.02item 9.01

  Pfizer Q2 adj EPS $0.60, revenue $13.3B; raises FY2024 guidance

  Revenues $13.3B, +2% YoY (+3% operational); non-COVID revenue grew 14% operationally.

• July 10, 2024, 7:59 PM ET leadership materiality 0.60 neutral item 5.02 ◈ executive_change

  Pfizer begins external search for successor to Chief Scientific Officer Mikael Dolsten

  CSO and President of R&D Mikael Dolsten to step down after over 15 years; external search launched.

• May 22, 2024, 7:59 PM ET other material materiality 0.75 neutral item 2.05

  Pfizer launches multi-year COGS reduction program; targets $1.5B savings by 2027

  First phase of cost-reduction program expected to deliver ~$1.5B savings by end of 2027.

• May 1, 2024, 7:59 PM ET earnings materiality 0.75 neutral item 2.02item 9.01 ◈ Earnings Releases

  Pfizer Q1 revenue $14.9B (-20% YoY); adj. EPS $0.82; raises FY adj. EPS guidance

  Q1 revenue $14.9B, operational decline 19% YoY; ex-COVID products grew 11% operationally.

• January 30, 2024, 6:59 PM ET earnings materiality 0.80 neutral item 2.02item 9.01 ◈ Earnings Releases ×3

  Pfizer posts FY2023 revenue $58.5B, adj EPS $1.84; reaffirms FY2024 guidance

  Full-year 2023 revenues $58.5B, down 41% operationally; reported diluted EPS $0.37, down 93%; adjusted diluted EPS $1.84, down 72%.

• December 14, 2023, 6:59 PM ET M&A materiality 0.90 positive item 2.02item 2.01item 7.01item 9.01 ◈ M&A Transactions

  Pfizer completes $43B acquisition of Seagen; Seagen becomes wholly owned subsidiary

  Acquisition closed Dec 14, 2023; $229 per share in cash for total enterprise value approx. $43 billion.

• December 14, 2023, 6:59 PM ET M&A materiality 0.95 positive item 2.01item 7.01item 9.01 ◈ M&A Transactions

  Pfizer completes $43B acquisition of Seagen at $229/share, expanding oncology portfolio

  Pfizer acquired Seagen for $229 per share in cash, total enterprise value of ~$43 billion.

• December 13, 2023, 6:59 PM ET earnings materiality 0.75 neutral item 7.01item 9.01

  Pfizer guides FY2024 rev $58.5-61.5B, adj EPS $2.05-2.25; Seagen closing Dec 14

  FY2024 revenue guidance $58.5-$61.5B; includes ~$8B from Comirnaty/Paxlovid and ~$3.1B from Seagen.

• December 12, 2023, 6:59 PM ET M&A materiality 0.90 positive item 5.02item 7.01item 9.01 ◈ executive_change ×4

  Pfizer expects to close Seagen acquisition on Dec 14; all regulatory approvals received

  Expects to close Seagen acquisition on Dec 14, 2023 after receiving all required regulatory approvals.

Executive changes

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.95 · Median 0.75 · Most common event earnings

9 positive 2 negative 17 neutral

source · PFE on sec.gov